Discovery and Optimization of Macrocyclic Quinoxaline-pyrrolo-dihydropiperidinones as Potent Pim-1/2 Kinase Inhibitors
                                
                                    
                                        作者:Victor J. Cee、Frank Chavez、Bradley Herberich、Brian A. Lanman、Liping H. Pettus、Anthony B. Reed、Bin Wu、Ryan P. Wurz、Kristin L. Andrews、Jie Chen、Dean Hickman、Jimmy Laszlo、Matthew R. Lee、Nadia Guerrero、Bethany K. Mattson、Yen Nguyen、Christopher Mohr、Karen Rex、Christine E. Sastri、Paul Wang、Qiong Wu、Tian Wu、Yang Xu、Yihong Zhou、Jeffrey T. Winston、J. Russell Lipford、Andrew S. Tasker、Hui-Ling Wang                                    
                                    
                                        DOI:10.1021/acsmedchemlett.5b00403
                                    
                                    
                                        日期:2016.4.14
                                    
                                    The identification of Pim-1/2 kinase overexpression in B-cell malignancies suggests' that Pim kinase inhibitors will have utility in the treatment of lymphoma, leukemia, and multiple myeloma. Starting from a moderately potent quinoxalinedihydropyrrolopiperidinone lead, we recognized the potential for macrocyclization and developed a series of 13-membered macro cycles. The structure activity relationships of the macrocyclic linker were systematically explored, leading to the identification of 9c as a potent, subnanomolar inhibitor of Pim-1 and -2. This molecule also potently inhibited Pim kinase activity in KMS-12-BM, a multiple myeloma cell line with relatively high endogenous levels of Pim-1/2, both in vitro (pBAD IC50 = 25 nM) and in vivo (pBAD EC50 = 30 nM, unbound), and a 100 mg/kg daily dose was found to completely arrest the growth of KMS-12-BM xenografts in mice.